Effects of an Emollient Containing Postbiotic Saccharomyces and Lactobacillus on Pediatric Atopic Dermatitis

Exclusion Criteria

• •1. Do not meet the diagnostic criteria established by Williams.
• •2. Children with acute exacerbation characterized by erosion, exudation, or secondary infection.
• •3. Presence of open skin infections (bacterial, viral, or fungal) at the application site.
• •4. Children currently participating in other clinical studies or having participated within the last 3 months.
• •5. Children who have received topical medication within 14 days prior to enrollment, including calcineurin inhibitors (e.g., topical tacrolimus or pimecrolimus), corticosteroid formulations, or topical antihistamines.
• •6. Children who have received non-steroidal immunosuppressants (e.g., cyclosporine, methotrexate) or phototherapy, systemic corticosteroids, or systemic antihistamines within 4 weeks prior to enrollment.
• •7. Children with severe immune system disorders (such as lymphoma, AIDS, Wiskott-Aldrich syndrome) or a history of malignant tumors.
• •8. Children with severe heart, liver, or kidney diseases.
• •9. Children with other skin diseases in the treatment area besides atopic dermatitis.
• •10. Known allergy to hydrocortisone butyrate cream or the test product.
• •11. Poor compliance of the subject, known inability to attend visits on time, or unwillingness to comply with the study protocol during the study period.
• •12. Any condition or previous/concurrent treatment that makes the subject ineligible for this study.